Brief: Foghorn Therapeutics Says FDA Has Lifted Clinical Hold On Phase 1 Study Of FHD-286

Foghorn Therapeutics

05/06/2023 12:12

June 5 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS ANNOUNCES FDA HAS LIFTED CLINICAL
HOLD
ON PHASE 1 STUDY OF FHD-286 IN RELAPSED AND/OR REFRACTORY
AML/MDS PATIENTS
    * FOGHORN THERAPEUTICS INC. - FOGHORN REITERATES GUIDANCE OF
CASH
RUNWAY INTO H2'2025
    * FOGHORN THERAPEUTICS INC. - FOGHORN REITERATES GUIDANCE OF
CASH
RUNWAY INTO H2'2025
    * FOGHORN - PLAN TO START PHASE 1 STUDY OF FHD-286 IN
COMBINATION
WITH DECITABINE OR CYTARABINE IN RELAPSED AND/OR REFRACTORY AML
PATIENTS IN Q3'2023

Source text for Eikon:  ID:nGNX7Y2st6 
Further company coverage:  FHTX.O